Clinical trial
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics…
NCT03020160 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT03020160 |
|---|---|
| Title | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A |
| Official title | A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks (Q4W) in Patients With Hemophilia A |
| Acronym | HAVEN 4 |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Chugai Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Emicizumab |
| Enrollment | 48 |
| Start date | Jan 30, 2017 |
| Primary completion | Dec 15, 2017 |
| Completion | Jun 29, 2022 |
| First posted | Jan 13, 2017 |
| Last update posted | Jan 11, 2023 |
| Countries | Australia, Belgium, Japan, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: